Astrazeneca Pharma India Ltd

{"amount":32}

{"description":"AstraZeneca Pharma India’s Q4FY26 net profit fell 23% to ₹44.8 crore despite 20.4% revenue growth to ₹578.6 crore; FY26 revenue reached ₹2,275.6 crore and the board recommended ₹36/share dividend.","url":"https://www.cnbctv18.com/market/astrazeneca-pharma-india-q4-profit-drops-23-despite-strong-revenue-growth-ws-l-19913862.htm","sentiment":"Negative","domain":"CNBCTV18"}

{"description":"AstraZeneca Pharma India hit an all-time high after its Enhertu drug won FDA priority review, a regulatory step that can speed approval and boost the drug’s growth prospects.","url":"https://www.zeebiz.com/markets/stocks/news-astrazeneca-hits-an-all-time-high-after-its-enhertu-medicine-gets-fda-priority-review-bse-nse-astrazeneca-share-price-274177","sentiment":"Positive","domain":"Zee Business"}

{"description":"AstraZeneca India receives CDSCO approval for a new Imfinzi indication, allowing durvalumab with carboplatin and paclitaxel as a first-line treatment for endometrial cancer.","url":"https://www.cnbctv18.com/market/stocks/astrazeneca-pharma-share-price-gets-cdsco-nod-for-new-imfinzi-indication-endometrial-cancer-19629982.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"AstraZeneca Pharma India Ltd., established in 1979, is a mid-cap company in the pharmaceuticals sector with a market cap of Rs 22,177.50 Crore. Current share price details are available live on NSE/BSE.","url":"https://economictimes.indiatimes.com/astrazeneca-pharma-india-ltd/stocks/companyid-13987.cms","sentiment":"Neutral","domain":"Indiatimes"}